Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion

Dow Jones - HealthThursday, September 18, 2025 at 1:56:00 PM
PositiveHealth
Roche to Buy Maker of Fatty Liver Treatment 89bio for Up to $3.5 Billion
Roche's recent decision to acquire 89bio for up to $3.5 billion is a significant move aimed at enhancing its drug pipeline. This acquisition focuses on an experimental treatment for fatty liver disease, a condition increasingly associated with obesity. By investing in this promising therapy, Roche not only expands its portfolio but also addresses a growing health concern, potentially improving outcomes for many patients.
— Curated by the World Pulse Now AI Editorial System

Was this article worth reading? Share it

Latest from Health
RFK Jr.’s Vaccine Committee to Vote on Hepatitis B and Covid Shots
NeutralHealth
RFK Jr.'s Vaccine Committee is set to vote on the inclusion of Hepatitis B and COVID-19 vaccines in its recommendations. This decision is significant as it could influence public health policies and vaccination strategies, especially in the context of ongoing debates about vaccine safety and efficacy. The outcome may also impact how these vaccines are perceived by the public and their uptake in various communities.
CDC panel votes to change guidance on MMRV vaccine for kids
NeutralHealth
The CDC's Advisory Committee on Immunization Practices has voted to revise its recommendations regarding the MMRV vaccine, which protects against measles and chickenpox. The new guidance advises against administering this vaccine to children under four years old due to a slight risk of febrile seizures in that age group. This change is significant as it aims to enhance the safety of vaccinations for young children while still promoting overall immunization against preventable diseases.
CDC advisory panel recommends restricting access to the MMRV vaccine
NegativeHealth
The CDC's advisory panel has voted to restrict access to the MMRV vaccine, which protects against measles and chickenpox. This decision raises concerns about public health, as it may limit vaccination options for children and could lead to increased outbreaks of these preventable diseases. It's crucial to monitor how this change will impact vaccination rates and community immunity.
Health Secretary Robert F. Kennedy Jr.’s handpicked slate of vaccine advisers voted to no longer recommend a combined shot for measles, mumps, rubella and varicella for children under age 4
NeutralHealth
Health Secretary Robert F. Kennedy Jr. has influenced a key committee to stop recommending a combined vaccine for measles, mumps, rubella, and varicella for children under four. This change reflects a growing trend where some states and insurers are beginning to diverge from established vaccination guidelines. It's significant because it could impact vaccination rates and public health strategies, raising questions about the future of childhood immunizations.
Kennedy Announces Firing of Organ Transplant Group After Safety Problems
NegativeHealth
In a significant move, Kennedy has announced the firing of the organ transplant group due to ongoing safety problems. This decision highlights serious concerns about patient safety and the quality of care in organ transplantation. It matters because it underscores the importance of accountability in healthcare, ensuring that organizations prioritize the well-being of patients above all else.
RKF Jr.'s hand-picked committee changed its recommendations for key childhood shots
NeutralHealth
A committee selected by Robert F. Kennedy Jr. has voted 8 to 3 to alter its recommendations regarding vaccinations for American children against diseases like measles, mumps, rubella, and chickenpox. This change is significant as it reflects ongoing debates about childhood vaccinations and public health policies, potentially influencing parental choices and health outcomes for children.